Johnson & Johnson (J&J) has filed with the World Health Organization (WHO) for an Emergency Use Listing (EUL) for its COVID-19 vaccine — a listing that would clear the way for the vaccine to be distributed through the WHO’s COVAX vaccine-sharing program.

J&J reached an agreement in December with Gavi, the Vaccine Alliance, a co-leader of COVAX, to provide up to 500 million vaccine doses through 2022.

To support the EUL filing, J&J submitted data from an ongoing global phase 3 trial, in which the vaccine showed 66 percent efficacy in preventing moderate-to-severe infection 28 days after inoculation.

The one-dose vaccine also demonstrated 85 percent efficacy in preventing severe disease and provided full protection against COVID-19-related hospitalization and death, including against the variant strain first identified in South Africa.